Arxada to invest in Visp facility, doubles-down on DSM collab

By Julia Wray 24-Aug-2022

The sum of CHF20m has been earmarked to grow the Swiss facility and reduce the site’s carbon footprint

Arxada to invest in Visp facility, doubles-down on DSM collab

Speciality chemicals firm Arxada has extended its collaboration with DSM for the supply of niacin and other nutritional ingredients from Arxada’s facility in Visp, Switzerland to DSM’s vitamin and ingredients business in neighbouring Visp-Lalden.

As part of this partnership extension, Arxada will invest CHF20m in its Visp production facility.

This investment will be used to expand production lines at the site and increase Arxada’s output of nutritional ingredients supplied to DSM.

Arxada will also make further investments to reduce the carbon footprint of the Visp site to help meet the sustainability commitments of both companies.

This follows Arxada’s significant investment in Visp in 2021 to reduce other greenhouse gas emissions at the site.

“We are delighted to be extending our agreement with DSM and building on the longstanding, mutually beneficial partnership with our neighbours in the Swiss Valais canton.

“This significant new investment in our Visp facility secures the site’s long term future, helping to fuel our future growth, and demonstrates our clear commitment to sustainability and reducing our carbon footprint,” Antje Gerber, President of Specialty Products Solutions at Arxada commented.

Arxada, which rebranded from Lonza Specialty Ingredients (LSI) in 2021, has been making its presence known in the speciality ingredients industry since the business’ purchase by Bain Capital and Cinven from Lonza Group earlier that year.

Sign up for your free email newsletter

In November 2021, it announced both its merger with Troy to create an antimicrobial powerhouse (finalised at the start of 2022) and a CHF20m in its Czech industrial biotech plant in Kouřim.

Companies